Evidence-led Adoption Centese’s Thoraguard digital drainage system has been evaluated in multiple clinical settings, including Stanford University Medical Center analyses and peer‑reviewed studies. This body of evidence supports a strong value proposition for pilots at high‑volume cardiothoracic and lung surgery programs. A sales focus on outcome‑driven procurement with clinical champions can accelerate adoption.

Strategic Growth Leadership The appointment of Timothy Still to Centese’s Board of Directors in February 2024 signals strategic growth and governance strength. Leverage this leadership expansion to pursue co‑development, investment, or distribution partnerships with larger medtech firms and major hospital networks.

Scalable Partnerships With a lean team and limited revenue scale, Centese offers opportunities for scalable partnerships such as contract manufacturing, OEM collaborations, or regional distribution agreements to accelerate market reach domestically and internationally.

Data Integration Centese’s digital platform orientation and software tools open avenues for data integration, analytics dashboards, and EHR interoperability to demonstrate clinical and financial value beyond hardware. Propose pilots that track outcomes and support HIPAA‑compliant data sharing with hospital IT teams.

Academic Expansion Centese has a track record of clinical validation across leading centers and publications and can expand its KOL network to drive multi‑site deployments. Focus outreach on academic medical centers and surgery programs to broaden adoption and generate additional peer‑reviewed evidence.